Evidence map›Paper›PMID 42141175›Full record

ArticleNature cancer2026

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.

Anuradha Jayaram, Memuna Rashid, Alison H M Reid, Francesco Orlando, Suparna Thakali, Leila Zakka, Miriam Goncalves, Jacqueline O'Dwyer, Constantine Alifrangis, Rob Jones and 19 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04067713 (Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04067713 active not recruitingnot on this map

Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer

TypeobservationalSponsorUniversity College, LondonRan2019 to 2030Enrolled192ConditionsMetastatic Prostate Cancer
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Anuradha JayaramUniversity College London Cancer Institute, London, UK.
Memuna RashidCancer Research UK and University College London Cancer Trials Centre, University College London, London, UK.
Alison H M ReidThe Royal Marsden NHS Foundation Trust, London, UK.
Francesco OrlandoLaboratory of Computational and Functional Oncology, Department of Cellular, Computational, and Integrative Biology, University of Trento, Trento, Italy.
Suparna ThakaliUniversity College London Cancer Institute, London, UK.
Leila ZakkaUniversity College London Cancer Institute, London, UK.
Miriam GoncalvesUniversity College London Cancer Institute, London, UK.
Jacqueline O'DwyerThe Christie NHS Foundation Trust, Manchester, UK.
Constantine AlifrangisDepartment of Oncology, University College London Hospitals NHS Trust, London, UK.
Rob JonesUniversity of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Elias PintusGuy's and St Thomas' NHS Foundation Trust, London, UK.
Sarah NeedlemanRoyal Free NHS Foundation Trust, London, UK.
Diletta BianchiniMedway Maritime Hospital NHS Foundation Trust, Gillingham, UK.
Anna WingateUniversity College London Cancer Institute, London, UK.
Kenrick NgBart's Health NHS Trust, London, UK.
Mark LinchUniversity College London Cancer Institute, London, UK.
Ursula McGovernUniversity College London Cancer Institute, London, UK.
John StaffurthVelindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK.
Simon J CrabbUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.ORCID http://orcid.org/0000-0003-3521-9064
Susannah BrockRoyal Bournemouth Hospital, Bournemouth, UK.
Alison BirtleLancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
Osvaldas VainauskasUniversity College London Cancer Institute, London, UK.
Gianmarco LeoneUniversity College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6481-0115
Millenn ChiweweCancer Research UK and University College London Cancer Trials Centre, University College London, London, UK.
Allan HackshawCancer Research UK and University College London Cancer Trials Centre, University College London, London, UK.ORCID http://orcid.org/0000-0002-5570-5070
Andre LopesCancer Research UK and University College London Cancer Trials Centre, University College London, London, UK.ORCID http://orcid.org/0000-0002-1405-7337
Daniel WetterskogUniversity College London Cancer Institute, London, UK.
Francesca DemichelisLaboratory of Computational and Functional Oncology, Department of Cellular, Computational, and Integrative Biology, University of Trento, Trento, Italy.ORCID http://orcid.org/0000-0002-8266-8631
Gerhardt AttardUniversity College London Cancer Institute, London, UK. g.attard@ucl.ac.uk.ORCID http://orcid.org/0000-0002-4811-7983

Funding

Cancer Research UK (CRUK) A26822Prostate Cancer UK MA-TR15-007RCUK | Medical Research Council (MRC) MR/X001636/1
6 · The paper itself

Abstract

The prognosis of newly diagnosed metastatic prostate cancer is highly variable. The primary objective of the PARADIGM prospective cohort study was to evaluate predictors of survival in blood collected at the start of each of the first six treatment cycles from 114 patients with high-volume metastatic prostate cancer (biologically male) who were starting androgen deprivation therapy in combination with docetaxel or an androgen receptor pathway inhibitor. Here circulating tumor DNA (ctDNA) was detected in 29% of patients after 6-12 weeks of combination therapy (compared to 70% before any treatment) and associated with 12 month overall survival of 73% versus 99% for patients who were ctDNA-negative and 24 month survival of 50% versus 85%. The secondary objective was to test ctDNA with serum prostate-specific antigen (PSA). In multivariable models, both were independent risk factors on combination treatment with a hazard ratio of death of 20.34 for the poorest prognosis group, but only ctDNA was associated with shorter survival on androgen deprivation before the start of combination therapy. Using ctDNA with serum PSA and clinical characteristics can improve the accuracy of survival prediction and should be evaluated for ctDNA-informed treatment modification. ClinicalTrials.gov: NCT04067713 .

Indexed as

Biomarkers, TumorCirculating Tumor DNAProstate-Specific AntigenProstatic NeoplasmsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesDocetaxelHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProspective StudiesAndrogen AntagonistsBiomarkers, TumorCirculating Tumor DNADocetaxelProstate-Specific AntigenTaxoids

Identifiers

PMID42141175
PMCPMC13309274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.